Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL2-BAAG: Sequential Regimen in R/R CLL
NCT03787264Phase 2Completed
- Sponsor
- German CLL Study Group
- Start
- Jan 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib in chronic lymphocytic leukemia (CLL), sponsored by German CLL Study Group. Started Jan 2019; status: completed.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03787264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03787264.